Clinical Trials Directory

Trials / Completed

CompletedNCT05649462

Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis

Retrospective Analysis of the Effect of Vitamin D Supplementation on the Clinical Efficacy of Vedelizumab in Ulcerative Colitis Patients

Status
Completed
Phase
Study type
Observational
Enrollment
80 (actual)
Sponsor
Second Affiliated Hospital of Wenzhou Medical University · Academic / Other
Sex
All
Age
15 Years – 65 Years
Healthy volunteers

Summary

It is uncertain whether vitD3 supplementation is beneficial for the remission of ulcerative colitis (UC). The effects of vitD3 supplements on the efficacy of vidrecizumab in Chinese UC patients were retrospectively analyzed. Methods: Patients with moderate to severe UC were recorded. These patients were initially treated with VDZ. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of VDZ and continued throughout the follow-up period. Disease activity was assessed using the modified Mayo score.

Conditions

Timeline

Start date
2020-01-01
Primary completion
2021-11-01
Completion
2022-06-01
First posted
2022-12-14
Last updated
2022-12-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05649462. Inclusion in this directory is not an endorsement.

Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis (NCT05649462) · Clinical Trials Directory